Clinical trials: Arterial Stiffness
Hypertension
Study of the Safety and Efficacy of LCZ696 on Arterial Stiffness in Elderly Patients With Hypertension
The study examined the efficacy of LCZ696 in comparison to the ARB olmesartan on Central Aortic Systolic Blood Pressure (CASP) and other measures of central hemodynamics and arterial stiffness in elderly patients with an elevated…
- Trial name
- NCT01692301
- Testing
- LCZ696, Olmesartan, amlodipine
- Where
- 47 sites in United States, Argentina and 10 more
- Volunteers
- 454 people
- Sponsor
- Novartis Pharmaceuticals
Hypertension
LAAS (Losartan Anti-Atherosclerosis Study)(0954-330)(COMPLETED)
The primary objective of this study is to evaluate efficacy, arterial stiffness measured by Pulse Wave Velocity (PWV) of Losartan potassium group compared to Carvedilol group after 24 weeks of treatment in patients with the…
- Trial name
- NCT00496834
- Testing
- losartan potassium, Comparator: carvedilol, Comparator: losartan (+) hydrochlorothiazide (HCTZ)
- Volunteers
- 201 people
- Sponsor
- Organon and Co
Rheumatoid Arthritis
A Study of the Effect of Tocilizumab on Markers of Atherogenic Risk in Patients With Moderate to Severe Rheumatoid Arthritis
This 2 arm study will investigate the effects of tocilizumab on lipids, arterial stiffness, and markers of atherogenic risk in patients with moderate to severe active rheumatoid arthritis.
- Trial name
- NCT00535782
- Testing
- Tocilizumab, Methotrexate
- Where
- 40 sites in United States, Canada and 2 more
- Volunteers
- 132 people
- Sponsor
- Hoffmann-La Roche
Pulmonary Disease, Chronic Obstructive
A 16-Week Study to Evaluate the Effect of Advair DISKUS™ 250/50mcg on Arterial Stiffness in Subjects With Chronic Obstructive Pulmonary Disease (COPD)
The purpose of this study is to evaluate in patients with Chronic Obstructive Pulmonary Disease (COPD) if Advair DISKUS™ 250/50mcg BID modifies arterial stiffness which is a measure associated with risk of heart disease.
- Trial name
- NCT00857766
- Testing
- ADVAIR DISKUS™ 250/50mcg
- Where
- 24 sites in United States
- Volunteers
- 249 people
- Sponsor
- GlaxoSmithKline
Pulmonary Disease, Chronic Obstructive
Cardiovascular Function in COPD Patients
The objectives of the study are to explore the effect of treatment with tiotropium + olodaterol fixed dose combination (FDC) compared to fluticasone propionate + salmeterol FDC on: reversal of left ventricular diastolic…
- Trial name
- NCT03055988
- Testing
- Tiotropium, Olodaterol, Fluticasone propionate
- Where
- 10 sites in Germany
- Volunteers
- 76 people
- Sponsor
- Boehringer Ingelheim
Pulmonary Disease, Chronic Obstructive
A Study to Compare the Impact of Fulticasone Furoate/Vilanterol vs. Tiotropium on Arterial Stiffness in COPD
This study is designed to evaluate the effect of fluticasone furoate (FF, GW685698)/vilanterol (VI, GW642444) Inhalation Powder once daily (QD) on arterial stiffness compared with Tiotropium QD over 12 week treatment period in…
- Trial name
- NCT01395888
- Testing
- fluticasone furoate (FF, GW685698)/vilanterol (VI, GW642444) 100/25 mcg Novel Dry Powder Inhaler (NDPI), Tiotropium
- Where
- 55 sites in Argentina, France and 5 more
- Volunteers
- 260 people
- Sponsor
- GlaxoSmithKline
Diabetes Mellitus, Type 2
A Study of Postprandial Hyperglycemia in Participants With Type 2 Diabetes
This Study is looking at whether high blood glucose levels after a meal affect arterial stiffness more or less than low blood glucose levels, and whether certain cardiovascular markers influence the outcome of this.
- Trial name
- NCT01159938
- Testing
- Lispro
- Where
- Finland
- Volunteers
- 72 people, healthy volunteers welcome
- Sponsor
- Eli Lilly and Company
Pulmonary Disease, Chronic Obstructive
RELOVAIR® Lung Deflation Study
The primary objective of the study is to test the hypothesis that lung hyperinflation contributes to cardiac dysfunction in COPD and that the treatment of lung deflation with FF/VI Inhalation Powder 100/25 mcg administered once…
- Trial name
- NCT01691885
- Testing
- Fluticasone Furoate, Vilanterol
- Where
- United Kingdom
- Volunteers
- 45 people
- Sponsor
- GlaxoSmithKline
Pulmonary Disease, Chronic Obstructive
A 24-week Arterial Stiffness Study With Fluticasone Furoate/Vilanterol in COPD
The purpose of the study is to investigate the effect of fluticasone furoate/vilanterol Inhalation Powder on arterial stiffness compared with placebo and vilanterol over a 24-week treatment period in subjects with COPD and aortic…
- Trial name
- NCT01336608
- Testing
- Fluticasone Furoate/Vilanterol, Vilanterol
- Where
- 72 sites in United States, Germany and 4 more
- Volunteers
- 446 people
- Sponsor
- GlaxoSmithKline
Chronic Kidney Disease
Effects Of Sitaxsentan On Proteinuria, 24-Hour Blood Pressure, And Arterial Stiffness In Chronic Kidney Disease Subjects
This study is being conducted to evaluate sitaxsentan dosing in subjects with chronic kidney disease.
- Trial name
- FCRD01 (NCT00810732)
- Testing
- Open, Nifedipine
- Where
- 2 sites in United Kingdom
- Volunteers
- 27 people
- Sponsor
- Pfizer
No Disease
Efficacy of Polyphenols From Milk and Dark Chocolate
Dark chocolate is one of the richest sources of polyphenols though it has been hypothesised that the bioavailability and therefore probably the bioefficacy of epicatechin from milk chocolate was reduced compared to dark.
- Trial name
- NCT00513344
- Testing
- Dark Chocolate, Milk Chocolate, Control (polyphenol-free) "Chocolate"
- Where
- Switzerland
- Volunteers
- 6 people, healthy volunteers welcome
- Sponsor
- Société des Produits Nestlé (SPN)